VCYT Q4 2025 Earnings — Veracyte, Inc. Revenue & Financial Results | Market Cap Arena

VCYTVeracyte, Inc.

$3B

Q4 2025 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$141M+18.5% YoY

Gross Profit

$105M74.4% margin

Operating Income

$26M18.4% margin

Net Income

$41M29.3% margin

EPS (Diluted)

$0.50

QoQ Revenue Growth

+6.6%

Cash Flow

Operating Cash Flow

$53M

Free Cash Flow

$48M

Stock-Based Comp.

$11M

Balance Sheet

Total Assets

$1.4B

Total Liabilities

$96M

Stockholders' Equity

$1.3B

Cash & Equivalents

$363M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$141M	$119M	+18.5%
Gross Profit	$105M	$79M	+32.9%
Operating Income	$26M	$4M	+521.3%
Net Income	$41M	$5M	+704.8%

Revenue Segments

Testing

$136M97%

Product

$4M3%

Biopharmaceutical And Other

$686,0000%